Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHELTER: DAA Treatment for HCV-Negative Lung Transplant Recipients
NCT03724149Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Dec 2018
- Primary completion
- Dec 2021
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of grazoprevir, velpatasvir in hepatitis C (HCV), sponsored by University of Pennsylvania. Started Dec 2018; status: completed.
02
Drugs
grazoprevirvelpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03724149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724149.